Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Murat Akdere"'
Autor:
Hope Rugo, Stephen K. Chia, Javier Cortés, Giuseppe Curigliano, Patrick Neven, Rebecca Dent, Sara Tolaney, Eva Ciruelos, Yeon H. Park, Estelle Roux, Yogesh Chattar, Heather Patino, Murat Akdere, Dejan Juric
Publikováno v:
Cancer Research. 83:PD13-06
Introduction: PIK3CA mutations, seen in ~40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC), are associated with treatment (Tx) resistance and shorter s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2fb63b6ca37cb96be04ab06ec00d2c1
https://doi.org/10.1158/1538-7445.sabcs22-pd13-06
https://doi.org/10.1158/1538-7445.sabcs22-pd13-06
Autor:
Dejan Juric, Nicholas Turner, Sherene Loi, Fabrice Andre, Stephen K. Chia, Komal Jhaveri, Patrick Neven, Rebecca Dent, Eva Ciruelos, Mukta Joshi, Estelle Roux, Heather Patino, Murat Akdere, Hope Rugo
Publikováno v:
Cancer Research. 83:P4-09
Introduction: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) is mutated in ~40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a440c9c2e678ba158cd565892bfb8269
https://doi.org/10.1158/1538-7445.sabcs22-p4-09-12
https://doi.org/10.1158/1538-7445.sabcs22-p4-09-12
Autor:
Eva M Ciruelos, Florence Lerebours, Hope S Rugo, Manuel Ruiz-Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Patrick Neven, Yeon Hee Park, Nicholas Turner, Dejan Juric, Ennan Gu, Christina H Arce, Murat Akdere, Stephen Chia
Publikováno v:
Cancer Research. 82:P1-18
Introduction: In HR+, HER2- ABC, activating PIK3CA mutations occur in ~40% of tumors and confer worse prognosis, including endocrine therapy (ET) resistance. BYLieve (NCT03056755) is an ongoing Phase II, open-label, 3-cohort noncomparative study, eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e3e43f6413409edfa91d6789759b96b
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-03
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-03
Autor:
Stephen Chia, Eva M Ciruelos, Hope S Rugo, Florence Lerebours, Manuel Ruiz-Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Nicholas Turner, Ennan Gu, Christina Arce, Murat Akdere, Dejan Juric
Publikováno v:
Cancer Research. 82:P1-18
Introduction: PIK3CA (encoding phosphatidylinositol 3-kinase alpha [PI3Kα]) is a driver oncogene mutated (mut) in ~40% of HR+, HER2- ABCs, leading to endocrine therapy (ET) resistance and poor prognosis. Alpelisib (ALP) is the first oral α-selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bac0d3b6315a3676442e2df3b15c7e52
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-08
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-08
Autor:
Dejan Juric, Nicholas Turner, Aleix Prat, Stephen Chia, Eva M Ciruelos, Manuel Ruiz-Borrego, Pamela Drullinsky, Florence Lerebours, Thomas Bachelot, O. Alejandro Balbin, Mukta Joshi, Estelle Roux, Christina H Arce, Murat Akdere, Hope S Rugo
Publikováno v:
Cancer Research. 82:P5-13
Introduction: Alpelisib (ALP, a PI3Kα inhibitor and degrader) + ET has demonstrated efficacy in patients (pts) with HR+, HER2-, PIK3CA-mutated ABC progressing on/after CDK4/6i + ET in the ongoing Phase II BYLieve study (NCT03056755). The primary end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04727c17d76a87c9e9e71fa8c210eb80
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-03
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-03
Autor:
Hope S Rugo, Patrick Neven, Isabel Saffie, Yeon Hee Park, Michelino De Laurentiis, Florence Lerebours, Eva Maria Ciruelos, Nicholas Turner, Dejan Juric, Ennan Gu, Christina H Arce, Mukta Joshi, Estelle Roux, Murat Akdere, Stephen Chia
Publikováno v:
Cancer Research. 82:PD13-05
Introduction: Alpelisib (ALP), an inhibitor and degrader of phosphatidylinositol-3-kinase α (PI3Kα), + fulvestrant (FUL) demonstrated efficacy in PIK3CA-mutated, HR+, HER2- ABC in the phase 3 SOLAR-1 trial, which included only 20 patients (pts) wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47d5972c1288bd6132bd2e2cde286c88
https://doi.org/10.1158/1538-7445.sabcs21-pd13-05
https://doi.org/10.1158/1538-7445.sabcs21-pd13-05
Autor:
Yu-Ming Shen, Dejan Juric, Murat Akdere, Aleix Prat, Hope S. Rugo, Stephen Chia, Christina Arce, Florence Lerebours, Nicholas C. Turner, Eva Ciruelos, Pamela Drullinsky, Rafael Villanueva Vazquez
Publikováno v:
Cancer Research. 81:PD2-07
Introduction: Mutations in PIK3CA, which encodes the α-isoform of phosphatidylinositol 3-kinase (PI3Kα), occur in ~40% of patients (pts) with HR+, HER2- ABC and can contribute to endocrine resistance. Alpelisib (ALP), a PI3Kα-selective inhibitor a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0177127221592a9e20d0906b8b224c4d
https://doi.org/10.1158/1538-7445.sabcs20-pd2-07
https://doi.org/10.1158/1538-7445.sabcs20-pd2-07
Autor:
Dejan Juric, Hope S. Rugo, Stephen K.L. Chia, Florence Lerebours, Manuel Ruiz-Borrego, Pamela Drullinsky, Eva M. Ciruelos, Patrick Neven, Yeon Hee Park, Christina H. Arce, Ennan Gu, Mukta Joshi, Estelle Roux, Murat Akdere, Nicholas C. Turner
Publikováno v:
Journal of Clinical Oncology. 40:1018-1018
1018 Background: ALP (PI3K-α selective inhibitor and degrader) + fulvestrant (FUL) is approved for pts with HR+, HER2– ABC and a tumor mutation in PIK3CA (̃ 40% of these pts). Primary analyses from the Phase 2 BYLieve study demonstrated efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7669b2bb2b1ac09cf64988179de5b5a3
https://doi.org/10.1200/jco.2022.40.16_suppl.1018
https://doi.org/10.1200/jco.2022.40.16_suppl.1018
Autor:
Nick Turner, Hope S Rugo, Eva M Ciruelos, Manuel Ruiz-Borrego, Pamela Drullinsky, Florence Lerebours, Aleix Prat, Thomas Bachelot, Stephen Chia, Alejandro Balbin, Mukta Joshi, Estelle Roux, Christina H Arce, Murat Akdere, Dejan Juric
Publikováno v:
Cancer Research. 82:PD15-01
Introduction: Endocrine-based therapy is the standard of care for patients (pts) with HR+ ABC. Acquired ESR1 mutations (mut) have been reported in up to 56% of pts with HR+ ABC progressing after prior treatment with ET, and aromatase inhibitors (AIs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75c8e461b48d42b042a51c12f3eba37d
https://doi.org/10.1158/1538-7445.sabcs21-pd15-01
https://doi.org/10.1158/1538-7445.sabcs21-pd15-01
Autor:
Yeon Hee Park, Ines Lorenzo, Sibylle Loibl, Pamela Drullinsky, Dawn Aubel, Ginny Mason, Hope S. Rugo, Fabrice Andre, Eva Ciruelos, Fatima Cardoso, Murat Akdere
Publikováno v:
The Breast. 59:S49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaf9b1de31def260393f8d52349ee51a
https://doi.org/10.1016/s0960-9776(21)00547-6
https://doi.org/10.1016/s0960-9776(21)00547-6